Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$394 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.9
Industry P/E
--
EV/EBITDA
-5.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.9
Face value
--
Shares outstanding
63,503,269
CFO
$-195.85 Mln
EBITDA
$-223.91 Mln
Net Profit
$-214.47 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aura Biosciences Inc (AURA)
| 20.0 | 11.0 | 20.0 | 15.3 | -11.0 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Aura Biosciences Inc (AURA)
| -33.7 | -7.2 | -15.6 | -38.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aura Biosciences Inc (AURA)
|
6.5 | 394.2 | 1.2 | -106.5 | -8,717.3 | -74.8 | -- | 2.9 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs... or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Address: 80 Guest Street, Boston, MA, United States, 02135 Read more
Founder, CEO, President & Director
Dr. Elisabet de los Pinos Ph.D.
Founder, CEO, President & Director
Dr. Elisabet de los Pinos Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Aura Biosciences Inc (AURA) is $6.54 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Aura Biosciences Inc (AURA) has given a return of -11.01% in the last 3 years.
Since, TTM earnings of Aura Biosciences Inc (AURA) is negative, P/E ratio is not available.
The P/B ratio of Aura Biosciences Inc (AURA) is 2.88 times as on 31-Mar-2026, a 27 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-4.73
|
2.70
|
|
2023
|
-4.64
|
1.57
|
|
2022
|
-5.36
|
1.61
|
|
2021
|
-2.41
|
0.56
|
|
2020
|
--
|
--
|
The 52-week high and low of Aura Biosciences Inc (AURA) are Rs 7.48 and Rs 4.35 as of 04-Apr-2026.
Aura Biosciences Inc (AURA) has a market capitalisation of $ 394 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Aura Biosciences Inc (AURA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.16
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.